Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406445 | 0.87 | ERCC5 (0.46) | ERCC5FEN1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2475812 | 0.86 | F2R (0.43) | TAS1R3TAS1R1TAS1R2TSHRERCC5 | |
| SCHEMBL3406437 | 0.84 | SMN1; SMN2 (0.40) | ALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL5057138 | 0.83 | PTPN1 (0.50) | TSHRERCC5FEN1CES2CES1 | |
| SCHEMBL27596818 | 0.81 | F2R (0.46) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2255346 | 0.81 | ERCC5 (0.61) | TAS1R3TAS1R1TAS1R2TSHRERCC5 | |
| SCHEMBL2837238 | 0.80 | ERCC5 (0.58) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL1262256 | 0.79 | KLKB1 (0.47) | TAS1R3TAS1R1TAS1R2TSHRERCC5 | |
| SCHEMBL27598806 | 0.79 | HSP90AB1 (0.47) | ALDH1A1HPGDATMSMN1; SMN2NPC1 | |
| SCHEMBL5952356 | 0.79 | RXFP1 (0.41) | TSHRERCC5FEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115478079-A | Method for preparing bupropion intermediate by continuous flow method | 哈尔滨工业大学（深圳） | 2022-12-16 | — | — | CN | disclosed |
| CN-111875559-B | Thiazole hydrazide derivatives and application thereof as agricultural bactericide | 南京农业大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-108558686-B | Preparation method of bupropion hydrochloride | 绍兴文理学院元培学院 | 2020-11-06 | — | — | CN | disclosed |
| CN-111875559-A | Thiazole hydrazide derivatives and application thereof as agricultural bactericide | 南京农业大学 | 2020-11-03 | — | — | CN | disclosed |
| CN-108558686-A | A kind of preparation method of BUPROPIONE HCl | 绍兴文理学院元培学院 | 2018-09-21 | — | — | CN | disclosed |
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| CN-102056907-B | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2014-12-31 | — | — | CN | disclosed |
| CN-102015705-B | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2013-11-13 | — | — | CN | disclosed |
| CN-103214431-A | 2,3-dihydrobenzazapine*compound or its salt and its medical application | UNIV FUDAN | 2013-07-24 | — | — | CN | disclosed |
| CN-101784266-B | Bupropion hydrobromide and therapeutic applications | BIOVAIL LAB INT SRL | 2012-07-18 | — | — | CN | disclosed |
| CN-102341379-A | Derivatives of benzothiazines, preparation thereof and application thereof as drugs | PF MEDICAMENT | 2012-02-01 | — | — | CN | disclosed |
| CN-102149687-A | Novel imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV | 2011-08-10 | — | — | CN | disclosed |
| CN-102056907-A | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2011-05-11 | — | — | CN | disclosed |
| CN-102015705-A | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2011-04-13 | — | — | CN | disclosed |
| CN-101903016-A | Bupropion hydrobromide and therapeutic uses | BIOVAIL LAB INT SRL | 2010-12-01 | — | — | CN | disclosed |
| CN-101784266-A | The application of bupropion hydrobromide and treatment | BIOVAIL LAB INT SRL | 2010-07-21 | — | — | CN | disclosed |
| CN-101103007-A | Amide compound | TAKEDA PHARMACEUTICAL (JP) | 2008-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | TAS1R3 4722/4885TAS1R1 4534/4885TAS1R2 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.